Which has stronger earnings and valuation, SVA or NBP?

I-Mab has lower revenue, but higher earnings than Sinovac Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A I-Mab $3.89M 40.28 -$46.27M -$0.36 N/A

Is SVA or NBP more profitable?

Company Net Margins Return on Equity Return on Assets Sinovac Biotech N/A N/A N/A I-Mab N/A N/A N/A

Is NBP or AURA more profitable?

I-Mab's return on equity of 0.00% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets I-Mab N/A N/A N/A Aura Biosciences N/A -73.18% -62.00%

Which has better valuation & earnings, NBP or STTK?

I-Mab has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio I-Mab $3.89M 40.28 -$46.27M -$0.36 N/A Shattuck Labs $1M 675.42 -$48.81M -$0.51 N/A

Is NBP or STTK more profitable?

I-Mab's return on equity of 0.00% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets I-Mab N/A N/A N/A Shattuck Labs N/A -43.57% -40.90%

Does the media refer more to NBP or STTK?

In the previous week, Shattuck Labs had 7 more articles in the media than I-Mab. MarketBeat recorded 8 mentions for Shattuck Labs and 1 mentions for I-Mab. Shattuck Labs' average media sentiment score of 0.29 beat I-Mab's score of 0.00 indicating that Shattuck Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment I-Mab 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Shattuck Labs 0 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, NBP or NGNE?

I-Mab has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio I-Mab $3.89M 40.28 -$46.27M -$0.36 N/A Neurogene $930K 551.89 -$90.35M -$5.03 N/A

Is NBP or NGNE more profitable?

I-Mab's return on equity of 0.00% beat Neurogene's return on equity. Company Net Margins Return on Equity Return on Assets I-Mab N/A N/A N/A Neurogene N/A -45.10% -41.00%

Does the media refer more to NBP or NGNE?

In the previous week, Neurogene had 2 more articles in the media than I-Mab. MarketBeat recorded 3 mentions for Neurogene and 1 mentions for I-Mab. Neurogene's average media sentiment score of 0.50 beat I-Mab's score of 0.00 indicating that Neurogene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment I-Mab 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neurogene 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NBP or CTMX?

In the previous week, CytomX Therapeutics had 2 more articles in the media than I-Mab. MarketBeat recorded 3 mentions for CytomX Therapeutics and 1 mentions for I-Mab. CytomX Therapeutics' average media sentiment score of 0.14 beat I-Mab's score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment I-Mab 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CytomX Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

I-Mab (NBP) Competitors

$1.36 +0.02 (+1.12%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.36 0.00 (0.00%)

As of 10/2/2026 07:30 PM Eastern

Compare

NBP vs. SVA, AURA, STTK, NGNE, and CTMX

Should you buy I-Mab stock or one of its competitors? I-Mab's main competitors and comparable companies include Sinovac Biotech (SVA), Aura Biosciences (AURA), Shattuck Labs (STTK), Neurogene (NGNE), and CytomX Therapeutics (CTMX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does I-Mab compare to Sinovac Biotech?

Sinovac Biotech (NASDAQ:SVA) and I-Mab (NASDAQ:NBP) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

In the previous week, I-Mab had 1 more articles in the media than Sinovac Biotech. MarketBeat recorded 1 mentions for I-Mab and 0 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.00 equaled I-Mab'saverage media sentiment score.

Company	Overall Sentiment
Sinovac Biotech	Neutral
I-Mab	Neutral

38.4% of I-Mab shares are owned by institutional investors. 12.8% of Sinovac Biotech shares are owned by insiders. Comparatively, 22.1% of I-Mab shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

I-Mab has lower revenue, but higher earnings than Sinovac Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A
I-Mab	$3.89M	40.28	-$46.27M	-$0.36	N/A

Sinovac Biotech has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, I-Mab has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market.

Sinovac Biotech currently has a consensus price target of $1.00, indicating a potential downside of 84.54%. I-Mab has a consensus price target of $9.00, indicating a potential upside of 564.21%. Given I-Mab's higher possible upside, analysts clearly believe I-Mab is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
I-Mab	N/A	N/A	N/A

Summary

I-Mab beats Sinovac Biotech on 7 of the 9 factors compared between the two stocks.

How does I-Mab compare to Aura Biosciences?

I-Mab (NASDAQ:NBP) and Aura Biosciences (NASDAQ:AURA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

I-Mab's return on equity of 0.00% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Aura Biosciences	N/A	-73.18%	-62.00%

I-Mab has higher revenue and earnings than Aura Biosciences. I-Mab is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	40.28	-$46.27M	-$0.36	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A

I-Mab currently has a consensus price target of $9.00, suggesting a potential upside of 564.21%. Aura Biosciences has a consensus price target of $17.50, suggesting a potential upside of 187.36%. Given I-Mab's higher probable upside, equities analysts clearly believe I-Mab is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, I-Mab had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 1 mentions for I-Mab and 0 mentions for Aura Biosciences. I-Mab's average media sentiment score of 0.00 equaled Aura Biosciences'average media sentiment score.

Company	Overall Sentiment
I-Mab	Neutral
Aura Biosciences	Neutral

I-Mab has a beta of 1.59, indicating that its share price is 59% more volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market.

38.4% of I-Mab shares are held by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are held by institutional investors. 22.1% of I-Mab shares are held by company insiders. Comparatively, 1.9% of Aura Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

I-Mab beats Aura Biosciences on 9 of the 13 factors compared between the two stocks.

How does I-Mab compare to Shattuck Labs?

I-Mab (NASDAQ:NBP) and Shattuck Labs (NASDAQ:STTK) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

I-Mab's return on equity of 0.00% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Shattuck Labs	N/A	-43.57%	-40.90%

In the previous week, Shattuck Labs had 7 more articles in the media than I-Mab. MarketBeat recorded 8 mentions for Shattuck Labs and 1 mentions for I-Mab. Shattuck Labs' average media sentiment score of 0.29 beat I-Mab's score of 0.00 indicating that Shattuck Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Shattuck Labs	0 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

I-Mab presently has a consensus price target of $9.00, indicating a potential upside of 564.21%. Shattuck Labs has a consensus price target of $13.33, indicating a potential upside of 98.12%. Given I-Mab's higher probable upside, equities research analysts clearly believe I-Mab is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

I-Mab has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	40.28	-$46.27M	-$0.36	N/A
Shattuck Labs	$1M	675.42	-$48.81M	-$0.51	N/A

38.4% of I-Mab shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 22.1% of I-Mab shares are owned by insiders. Comparatively, 8.8% of Shattuck Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

I-Mab has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

Summary

I-Mab beats Shattuck Labs on 9 of the 16 factors compared between the two stocks.

How does I-Mab compare to Neurogene?

I-Mab (NASDAQ:NBP) and Neurogene (NASDAQ:NGNE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

I-Mab presently has a consensus price target of $9.00, suggesting a potential upside of 564.21%. Neurogene has a consensus price target of $83.67, suggesting a potential upside of 226.19%. Given I-Mab's higher possible upside, analysts plainly believe I-Mab is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

I-Mab has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market. Comparatively, Neurogene has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market.

38.4% of I-Mab shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 22.1% of I-Mab shares are owned by company insiders. Comparatively, 11.7% of Neurogene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

I-Mab has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	40.28	-$46.27M	-$0.36	N/A
Neurogene	$930K	551.89	-$90.35M	-$5.03	N/A

I-Mab's return on equity of 0.00% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Neurogene	N/A	-45.10%	-41.00%

In the previous week, Neurogene had 2 more articles in the media than I-Mab. MarketBeat recorded 3 mentions for Neurogene and 1 mentions for I-Mab. Neurogene's average media sentiment score of 0.50 beat I-Mab's score of 0.00 indicating that Neurogene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neurogene	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

I-Mab and Neurogene tied by winning 8 of the 16 factors compared between the two stocks.

How does I-Mab compare to CytomX Therapeutics?

I-Mab (NASDAQ:NBP) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

I-Mab has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market.

38.4% of I-Mab shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 22.1% of I-Mab shares are owned by insiders. Comparatively, 3.8% of CytomX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

CytomX Therapeutics has higher revenue and earnings than I-Mab. CytomX Therapeutics is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	40.28	-$46.27M	-$0.36	N/A
CytomX Therapeutics	$76.20M	7.32	-$17.37M	-$0.50	N/A

I-Mab presently has a consensus target price of $9.00, suggesting a potential upside of 564.21%. CytomX Therapeutics has a consensus target price of $11.90, suggesting a potential upside of 364.84%. Given I-Mab's higher probable upside, analysts clearly believe I-Mab is more favorable than CytomX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

I-Mab has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -435.21%. I-Mab's return on equity of 0.00% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
CytomX Therapeutics	-435.21%	-38.46%	-30.33%

In the previous week, CytomX Therapeutics had 2 more articles in the media than I-Mab. MarketBeat recorded 3 mentions for CytomX Therapeutics and 1 mentions for I-Mab. CytomX Therapeutics' average media sentiment score of 0.14 beat I-Mab's score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CytomX Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

CytomX Therapeutics beats I-Mab on 9 of the 17 factors compared between the two stocks.

Get I-Mab News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NBP vs. The Competition

Export

Metric	I-Mab	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$156.70M	$3.85B	$7.15B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.33%
P/E Ratio	-3.76	13.00	275.67	26.04
Price / Sales	40.28	1,289.24	656.66	111.00
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	0.68	16.57	10.93	6.31
Net Income	-$46.27M	-$22.66M	$3.51B	$362.16M
7 Day Performance	-1.81%	-2.97%	-2.00%	-1.66%
1 Month Performance	-24.72%	-10.82%	-6.19%	-4.68%
1 Year Performance	N/A	19.00%	8.03%	1.57%

I-Mab Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NBP I-Mab	1.612 of 5 stars	$1.36 +1.1%	$9.00 +564.2%	N/A	$156.70M	$3.89M	N/A	30	News Coverage Positive News
SVA Sinovac Biotech	0.8564 of 5 stars	$6.47 flat	$1.00 -84.5%	N/A	$644.66M	$386.01M	N/A	3,008	Positive News High Trading Volume
AURA Aura Biosciences	1.2866 of 5 stars	$6.00 -2.4%	$17.50 +191.7%	+0.7%	$637.78M	N/A	N/A	113	News Coverage
STTK Shattuck Labs	2.4378 of 5 stars	$6.07 -3.8%	$12.78 +110.5%	+186.4%	$633.29M	$1M	N/A	40	News Coverage Analyst Forecast Gap Up
NGNE Neurogene	2.8011 of 5 stars	$28.31 -9.4%	$83.67 +195.5%	+14.8%	$625.36M	$930K	N/A	131	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NBP) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

I-Mab (NBP) Competitors

NBP vs. SVA, AURA, STTK, NGNE, and CTMX

How does I-Mab compare to Sinovac Biotech?

Summary

How does I-Mab compare to Aura Biosciences?

Summary

How does I-Mab compare to Shattuck Labs?

Summary

How does I-Mab compare to Neurogene?

Summary

How does I-Mab compare to CytomX Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBP vs. The Competition

I-Mab Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

I-Mab (NBP) Competitors

NBP vs. SVA, AURA, STTK, NGNE, and CTMX

How does I-Mab compare to Sinovac Biotech?

Does the media favor SVA or NBP?

Do insiders & institutionals believe in SVA or NBP?

Which has stronger earnings and valuation, SVA or NBP?

Which has more risk and volatility, SVA or NBP?

Do analysts prefer SVA or NBP?

Is SVA or NBP more profitable?

Summary

How does I-Mab compare to Aura Biosciences?

Is NBP or AURA more profitable?

Which has preferable valuation and earnings, NBP or AURA?

Do analysts prefer NBP or AURA?

Does the media refer more to NBP or AURA?

Which has more volatility and risk, NBP or AURA?

Do insiders and institutionals hold more shares of NBP or AURA?

Summary

How does I-Mab compare to Shattuck Labs?

Is NBP or STTK more profitable?

Does the media refer more to NBP or STTK?

Do analysts recommend NBP or STTK?

Which has better valuation & earnings, NBP or STTK?

Do insiders and institutionals believe in NBP or STTK?

Which has more volatility & risk, NBP or STTK?

Summary

How does I-Mab compare to Neurogene?

Do analysts rate NBP or NGNE?

Which has more risk & volatility, NBP or NGNE?

Do institutionals & insiders hold more shares of NBP or NGNE?

Which has stronger valuation & earnings, NBP or NGNE?

Is NBP or NGNE more profitable?

Does the media refer more to NBP or NGNE?

Summary

How does I-Mab compare to CytomX Therapeutics?

Which has more volatility & risk, NBP or CTMX?

Do institutionals & insiders have more ownership in NBP or CTMX?

Which has higher valuation & earnings, NBP or CTMX?

Do analysts prefer NBP or CTMX?

Is NBP or CTMX more profitable?

Does the media refer more to NBP or CTMX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBP vs. The Competition

I-Mab Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools